Drugs / Bevacizumab
Bevacizumab
Drug Approved in the United States; prescription-onlyMonoclonal antibody; angiogenesis inhibitor·First approved·2004
- Registered trials
- 1750
- Ongoing
- 446/ 25%
- Completed
- 875
- Indications
- 6
Approved indications
| Indication |
|---|
| Colorectal cancer |
| Lung cancer |
| Ovarian cancer |
| Glioblastoma |
| Hepatocellular carcinoma |
| Renal-cell carcinoma |
Clinical trial landscape
1750 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 900 | 191 | 476 | |
| Phase 3 | 248 | 89 | 108 | |
| Phase 1 | 238 | 58 | 138 | |
| Phase 1/2 | 165 | 61 | 55 | |
| Unknown | 50 | 6 | 29 | |
| Not applicable | 47 | 14 | 22 | |
| Phase 4 | 47 | 8 | 27 | |
| Phase 2/3 | 36 | 12 | 13 | |
| Early Phase 1 | 19 | 7 | 7 | |
| All phases | 1750 | 446 | 875 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Inhibits VEGF-A signaling to reduce tumor blood vessel formation.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.